Kidney injury after hematopoietic stem cell transplantation
A narrative review maps acute and chronic kidney injury after HSCT by timing and transplant complications. It synthesizes prior evidence on AKI incidence, transplant-specific causes and long-term kidney follow-up.
Read more
Almalki L, Weber N, Devasia A, Kitchlu A. Cancers. 2026;18(21):3510. DOI: 10.3390/cancers18213510. Published October 31, 2026.
This narrative review covers AKI, transplant-specific complications, CKD and long-term kidney outcomes after hematopoietic stem cell transplantation (HSCT).
The review proposes a time-based differential spanning early infusion-related syndromes, sepsis and nephrotoxins, sinusoidal obstruction syndrome, GVHD-associated kidney injury, transplant-associated thrombotic microangiopathy and later glomerular disease and CKD.
It cites a prior meta-analysis of 36 cohorts and 5,144 adults that reported pooled AKI incidence of 55.1% (95% CI 46.6-63.3%) and stage 3 AKI of 8.3%. This is a synthesis of earlier cohorts, not a new trial or primary cohort. Treatment evidence for transplant-associated TMA remains mixed by study design and agent.